Researchers have identified a hidden virus inside a common gut bacterium that appears significantly more often in people with colorectal cancer than in those without it.
The finding reframes a long-standing mystery by pointing to a bacterial-viral partnership rather than a single microbe as the critical signal behind this deadly cancer.
Within patient samples where the same gut bacterium appeared in both healthy individuals and those with cancer, a crucial difference emerged in the genetic material carried inside it.
By examining these samples, Flemming Damgaard at the University of Southern Denmark and Odense University Hospital documented that cancer-linked strains consistently harbored a previously undetected virus.
That viral presence appeared repeatedly across cases tied to cancer, even when the bacterium itself remained otherwise common and widespread.
The pattern narrows the explanation for the bacterium’s inconsistent link to disease while leaving open whether the virus drives the process or simply marks a deeper change.
Worldwide, colorectal cancer is the third most common cancer and the second leading cause of cancer death.
Many cases seem tied to environment, so scientists keep searching the gut for clues.
The deeper problem was that Bacteroides fragilis, a common bacterium that normally lives in the human gut, kept showing up around tumors even though it is also common in healthy people.
That contradiction pushed the team to stop asking which species was present and start asking what each strain carried.
Studying the Denmark population, the trail began with an earlier Danish cohort that followed bloodstream infections across a population of about two million people.
Among 583 patients with B. Fragilis in the blood, 11 developed colorectal cancer within weeks and eight stored isolates anchored the search.
Since those samples came from patients who later did or did not secure cancer, the team could compare near matches.
Rather than uncovering a cancer-only strain, the search kept pointing to viral passengers inside otherwise familiar bacteria.
To see whether the signal held beyond Denmark, the researchers checked stool DNA from 877 adults in Europe, the United States, and Asia.
Across those datasets, people with colorectal cancer were about twice as likely to carry viral traces, with an odds ratio of 2.05.
Early screening analysis also found that six viral fragments detected 40.6 percent of cases at 83.3 percent specificity.
Those numbers make the virus interesting as a marker, even though they fall well short of a standalone screening tool.
Viruses that infect bacteria are called bacteriophages, viruses that utilize bacterial cells to copy themselves.
When one settles into bacterial DNA, it can change which genes the cell reads and alter behavior.
Hidden viruses in the gut are emerging as a new frontier in cancer research, and the virome may be just as vital as bacteria when it comes to colorectal cancer risk.
A newly described bacteriophage hiding inside common Bacteroides bacteria has been linked to roughly doubled odds of developing colorectal cancer, and it may one day serve as a non-invasive stool biomarker for earlier detection.
This finding is pushing scientists to seem beyond bacteria alone and consider how viral communities in the intestine shape health and disease.
Colorectal cancer starts in the colon or rectum, usually from small polyps that can become malignant over many years.
Because early stages often cause no symptoms, detection before spread is crucial for survival and treatment success.
For more on this story, see Yokohama City University researchers map protein structure to block herpes virus.
When found early, colorectal cancer is usually much more treatable and associated with better long-term outcomes.
Current screening tools include colonoscopy, sigmoidoscopy, fecal occult blood tests (FOBT/FIT), and stool DNA tests.
Colonoscopy is highly effective but invasive, requires bowel preparation, and can be difficult to access for some people.
Stool-based tests are simpler and non-invasive, but they can miss early cancers or advanced polyps.
These limitations drive interest in new stool biomarkers, including those that come from the gut virome, bacteriophages, and specific Bacteroides strains.
Most research on colorectal cancer and the gut has focused on the microbiome, the community of bacteria in the intestine.
Studies repeatedly show that certain bacteria, such as Fusobacterium and some Bacteroides species, are more common in people with colorectal cancer than in healthy controls.
These microbes may promote inflammation, produce toxins, or form biofilms that help tumors develop and escape immune defenses.
Alongside bacteria, the gut also hosts a rich virome, made up largely of bacteriophages, viruses that infect bacteria, not human cells.
Bacteriophages can integrate into bacterial genomes (as prophages) or lyse their hosts.
In doing so, they can change which bacteria are present and how they behave.
A bacterium carrying a particular prophage may produce more toxins, adhere more strongly to the gut lining, or interact differently with the immune system.
Because of these effects, the virome is now seen as an important factor in colorectal cancer.
Distinct bacteriophage patterns have been observed in stool samples from colorectal cancer patients.
These patterns suggest that certain phages, especially those linked to Bacteroides, could act as both contributors to disease and as stool biomarkers that signal increased risk.
Bacteroides is a major bacterial genus in the human colon and plays key roles in digestion and immune development.
Among its species, Bacteroides fragilis is widely present in healthy individuals.
Colorectal cancer is among the most common cancers in Western countries and remains a major cause of cancer-related deaths.
While factors like age, diet, and lifestyle are known to influence risk, the exact triggers behind the disease are still not fully understood.
In recent years, scientists have increasingly focused on the gut microbiome, the vast ecosystem of bacteria, viruses, and other microorganisms living in the digestive system.
Now, researchers from the University of Southern Denmark and Odense University Hospital have identified a previously unknown virus inside a common gut bacterium.
This follows our earlier report, Title: Scientists Identify Bat Coronaviruses Capable of Entering Human Cells via Key Receptors.
This virus appears more often in people with colorectal cancer, offering a new clue about how the disease may develop.
For years, researchers have linked one specific bacterium, Bacteroides fragilis, to colorectal cancer.
Still, this connection has been difficult to explain because the same bacterium is also found in most healthy individuals.
It has been a paradox that we repeatedly find the same bacterium in connection with colorectal cancer, while at the same time it is a completely normal part of the gut in healthy people.
To resolve this contradiction, the team investigated whether there might be important differences within the bacterium itself.
They found that there were.
The key difference turned out to be a virus living inside the bacterium.
In patients who later developed colorectal cancer, Bacteroides fragilis was much more likely to carry a specific bacteriophage, a virus that infects bacteria.
We have discovered a virus that has not previously been described and which appears to be closely linked to the bacteria we find in patients with colorectal cancer.
The researchers believe this virus represents entirely new types that have not been identified before.
It is not just the bacterium itself that seems interesting. It is the bacterium in interaction with the virus it carries.
Although the study shows a strong statistical link between the virus and colorectal cancer, it does not prove that the virus causes the disease.
We do not yet know whether the virus is a contributing cause, or whether it is simply a sign that something else in the gut has changed.
The discovery began with data from a large Danish population study involving about two million people.
Researchers focused on patients who had experienced serious bloodstream infections caused by Bacteroides fragilis.
A small portion of these individuals were diagnosed with colorectal cancer within weeks.
By comparing bacterial samples from patients with and without cancer, the team identified a clear pattern.
What does this discovery mean for future cancer screening?
The viral signature could one day serve as a non-invasive stool biomarker, but current accuracy is not yet sufficient for standalone use.
Does the virus cause colorectal cancer?
Researchers have not determined whether the virus drives cancer development or merely marks an underlying change in the gut environment.